

FORM PTO-1300 (REV. 1-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER WC131
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09/269903</b>
INTERNATIONAL APPLICATION NO. PCT/GB97/02726	INTERNATIONAL FILING DATE 06 October 1997	PRIORITY DATE CLAIMED 04 October 1996	
TITLE OF INVENTION Colonic Delivery of Weak Acid Drugs			
APPLICANT(S) FOR DO/EO/US WATTS, Peter James			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li><input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li><input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li><input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li><input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li><input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li><input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li><input type="checkbox"/> have been transmitted by the International Bureau.</li> <li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li><input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li><input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li><input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unexecuted)</li> <li><input type="checkbox"/> A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
Items 11. to 16. below concern document(s) or information included:			
<ol style="list-style-type: none"> <li><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li><input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li><input checked="" type="checkbox"/> A FIRST preliminary amendment. <ol style="list-style-type: none"> <li><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> </ol> </li> <li><input type="checkbox"/> A substitute specification.</li> <li><input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li><input checked="" type="checkbox"/> Other items or information: Copy of published application</li> </ol>			

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO. <b>PCT/GB97/02726</b>	ATTORNEY'S DOCKET NUMBER <b>WC131</b>
---	--	--

<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$ 970.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... 840.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... 760.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... 670.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... 96.00</p> <p style="text-align: center;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;">\$</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>20 - 20 =</td> <td></td> <td>x \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent claims</td> <td>4 - 3 =</td> <td></td> <td>x \$78.00</td> <td>\$ 78.00</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$260.00</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL OF ABOVE CALCULATIONS =</b></td> <td><b>\$ 1,048.00</b></td> </tr> <tr> <td colspan="4">Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).</td> <td style="text-align: center;">+</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>SUBTOTAL =</b></td> <td><b>\$ 1,048.00</b></td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL NATIONAL FEE =</b></td> <td><b>\$ 1,048.00</b></td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL FEES ENCLOSED =</b></td> <td><b>\$ 1,048.00</b></td> </tr> <tr> <td colspan="4"></td> <td>Amount to be refunded: \$</td> </tr> <tr> <td colspan="4"></td> <td>charged: \$</td> </tr> </tbody></table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	20 - 20 =		x \$18.00	\$	Independent claims	4 - 3 =		x \$78.00	\$ 78.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 1,048.00</b>	Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				+	<b>SUBTOTAL =</b>				<b>\$ 1,048.00</b>	Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$	<b>TOTAL NATIONAL FEE =</b>				<b>\$ 1,048.00</b>	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	<b>TOTAL FEES ENCLOSED =</b>				<b>\$ 1,048.00</b>					Amount to be refunded: \$					charged: \$	<p style="text-align: center;"><b>CALCULATIONS PTO USE ONLY</b></p>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																																																														
Total claims	20 - 20 =		x \$18.00	\$																																																														
Independent claims	4 - 3 =		x \$78.00	\$ 78.00																																																														
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$																																																														
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 1,048.00</b>																																																														
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				+																																																														
<b>SUBTOTAL =</b>				<b>\$ 1,048.00</b>																																																														
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$																																																														
<b>TOTAL NATIONAL FEE =</b>				<b>\$ 1,048.00</b>																																																														
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$																																																														
<b>TOTAL FEES ENCLOSED =</b>				<b>\$ 1,048.00</b>																																																														
				Amount to be refunded: \$																																																														
				charged: \$																																																														

a. ☒ A check in the amount of \$ 1,048.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 01-2507 in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-2507. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Patrea L. Pabst, Esq.  
 Arnall Golden & Gregory, LLP  
 2800 One Atlantic Center  
 1201 West Peachtree Street  
 Atlanta, Georgia 30309-3450  
 United States of America

SIGNATURE  
 Kevin W. King  
 NAME  
 42,737  
 REGISTRATION NUMBER

510 Rec'd PCT/70 02 APR 1999

IN THE UNITED STATES RECEIVING OFFICE  
FOR THE PATENT COOPERATION TREATY

Applicant: Peter James Watts

International Application No.: PCT/GB97/02726  
International Filing Date: 6 October 1997

U.S. Serial No.:  
Filed: 02 April 1999

Express Mail Label No: EL273009964US  
Date of Deposit: 02 April 1999

For: COLONIC DELIVERY OF WEAK ACID DRUGS

Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Sir:

Please amend the application as follows.

**In the Specification**

At page 1, below the title, please insert:

--Priority is claimed under 35 U.S.C. § 119 to PCT/GB97/02726, filed October 6, 1997,  
which corresponds to GB 9620709.07 filed October 4, 1996.--

At page 22, line 1, please delete "Claims" and insert --I claim:-- in place thereof.

**In the Claims**

1. (Amended) A controlled release composition [including] comprising pellets,  
wherein each pellet [comprising] comprises an inner core[, which core comprises, or is  
coated with,] comprising a drug[, which drug] which possesses

(a) a free acid group which can be converted into an alkali metal salt, and

(b) a pKa in the range 2.0 to 9.0,

[which] wherein the inner core is [subsequently] coated with a rate-controlling membrane that determines drug release,

wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0 than the corresponding compound containing a free acid group, and

wherein the composition is adapted to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition.

2. (Amended) [A composition as claimed in Claim] The composition of claim 1 wherein the drug is a thromboxane synthase A<sub>2</sub> inhibitor or a thromboxane A<sub>2</sub>/prostaglandin endoperoxide receptor antagonist.

3. (Amended) [A composition as claimed in Claim] The composition of claim 2 wherein the drug is ridogrel.

4. (Amended) [A composition as claimed in any one of Claims 1 to 3,] The composition of claim 1 wherein the rate-controlling membrane comprises a material which forms a water-insoluble, but water-permeable layer and from which release of the drug is by diffusion through the layer.

5. (Amended) [A composition as claimed in Claim 4,] The composition of claim 4 wherein the rate-controlling membrane is formulated from a methacrylate copolymer or ethylcellulose.

6. (Amended) [A composition as claimed in Claim 5,] The composition of claim 5 wherein the rate-controlling membrane is formulated from [ethylcellulose or Eudragit] EUDRAGIT<sup>TM</sup> NE30D.

7. (Amended) [A composition as claimed in Claim 6 where] The composition of claim 5 wherein the rate-controlling membrane is ethylcellulose.

8. (Amended) [A composition as claimed in any one of the preceding claims,] The composition of claim 1 wherein the inner core is a sugar sphere.

9. (Amended) [A composition as claimed in any one of the preceding claims,] The composition of claim 1 wherein the salt is at least 10 times more soluble than the free acid form of the drug at pH 4.5 to 8.0 at 37 °C.

10. (Amended) [A composition as claimed in any Claim 9,] The composition of claim 9 wherein the salt is at least 100 times more soluble than the free acid form of the drug.

11. (Amended) [A composition as claimed in any one of the preceding claims,] The composition of claim 1 wherein the salt is an alkali metal salt.

12. (Amended) [A composition as claimed in Claim 11,] The composition of claim 11 wherein the alkali metal is sodium or potassium.

13. (Amended) [A composition as claimed in any one of the preceding claims] The composition of claim 1 wherein the pellets are administered in a starch capsule coated with a combination of polymethacrylates that is designed to disintegrate and release the pellets in the terminal ileum or in the colon.

14. (Amended) [A composition as claimed in any one of the preceding claims] The composition of claim 1 wherein the drug is used for [the] a treatment selected from the group consisting of ulcerative colitis, Crohn's disease, irritable bowel syndrome, and inflammatory bowel disease.

15. (Amended) A [process] method for [the preparation of] making a composition [according to any one of the preceding claims which comprises] comprising pellets.

wherein each pellet comprises an inner core comprising a drug which possesses

(a) a free acid group which can be converted into an alkali metal salt, and

(b) a pKa in the range 2.0 to 9.0,

wherein the inner core is coated with a rate-controlling membrane that determines drug

release, wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0

than the corresponding compound containing a free acid group, and wherein the composition

is adapted to prevent release of drug until the composition reaches the terminal ileum or the

colon following oral administration of the composition, the method comprising

making a salt of the drug, and

coating [said] the salt onto the inner cores.

16. (Amended) [A process as claimed in Claim 15,] The method of claim 15 wherein the salt is prepared as part of a preparation process for the coating of the inner cores.

17. (Amended) A method of improving the controlled release profile of a drug with a rapidly changing solubility in the pH range 4.5 to 8.0, [which comprises administering a composition according any one of Claims 1 to 14 to a patient, preferably a human patient] the method comprising administering the drug in a composition comprising pellets, wherein each pellet comprises an inner core comprising the drug which possesses

(a) a free acid group which can be converted into an alkali metal salt and

(b) a pKa in the range 2.0 to 9.0,

wherein the inner core is coated with a rate-controlling membrane that determines drug

release, wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0

than the corresponding compound containing a free acid group, and wherein the composition

is adapted to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition.

Please cancel claim 18.

19. (Amended) A method of treatment of ulcerative colitis, Crohn's disease, irritable bowel syndrome, and/or inflammatory bowel disease, [which method comprises] the method comprising

administering to a patient in need of treatment a composition [according to any one of Claims 1 to 14 to a patient, preferably a human patient] comprising pellets,

wherein each pellet comprises an inner core comprising a drug which possesses

(a) a free acid group which can be converted into an alkali metal salt, and

(b) a pKa in the range 2.0 to 9.0,

wherein the inner core is coated with a rate-controlling membrane that determines drug release, wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0 than the corresponding compound containing a free acid group, and wherein the composition is adapted to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition.

Please cancel claim 20.

Please add the following new claims.

21. (New) The composition of claim 1 wherein the pellets are compressed into tablets which are coated to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition.

22. (New) The composition of claim 1 wherein the core is between about 0.3 to 5 mm in size.


### Remarks

The specification has been amended to reference the priority application.

Claims 1-20, as shown in the published PCT application with amended sheets 22-24 attached to the response to second written opinion, are pending prior to entry of this Preliminary Amendment. Claims 18 and 20 have been canceled, and claims 1-17 and 19 have been amended to eliminate multiple dependencies, to use Markush groups where appropriate, and to clarify the claimed compositions and methods. New claims 21 and 22 have been added. Support for these claims is found at least on page 7, lines 2-4 and lines 11-13. No new matter has been added.

Allowance of claims 1-17, 19, 21, and 22 is earnestly solicited.

Respectfully submitted,

  
\_\_\_\_\_  
Kevin W. King  
Reg. No. 42,737

Date: 02 April 1999

ARNALL, GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8596  
(404) 873-8597



**APPENDIX**  
*Claims as Preliminarily Amended*

1. (Amended) A controlled release composition [including] comprising pellets, wherein each pellet [comprising] comprises an inner core, which core comprises, or is coated with,] comprising a drug, which drug] which possesses

(a) a free acid group which can be converted into an alkali metal salt, and

(b) a pKa in the range 2.0 to 9.0,

[which] wherein the inner core is [subsequently] coated with a rate-controlling membrane that determines drug release,

wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0 than the corresponding compound containing a free acid group, and

wherein the composition is adapted to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition.

2. (Amended) [A composition as claimed in Claim] The composition of claim 1 wherein the drug is a thromboxane synthase A<sub>2</sub> inhibitor or a thromboxane A<sub>2</sub>/prostaglandin endoperoxide receptor antagonist.

3. (Amended) [A composition as claimed in Claim] The composition of claim 2 wherein the drug is ridogrel.

4. (Amended) [A composition as claimed in any one of Claims 1 to 3,] The composition of claim 1 wherein the rate-controlling membrane comprises a material which forms a water-insoluble, but water-permeable layer and from which release of the drug is by diffusion through the layer.

5. (Amended) [A composition as claimed in Claim 4,] The composition of claim 4 wherein the rate-controlling membrane is formulated from a methacrylate copolymer or ethylcellulose.

6. (Amended) [A composition as claimed in Claim 5,] The composition of claim 5 wherein the rate-controlling membrane is formulated from [ethylcellulose or Eudragit] EUDRAGIT<sup>TM</sup> NE30D.

7. (Amended) [A composition as claimed in Claim 6 where] The composition of claim 5 wherein the rate-controlling membrane is ethylcellulose.

8. (Amended) [A composition as claimed in any one of the preceding claims,] The composition of claim 1 wherein the inner core is a sugar sphere.

9. (Amended) [A composition as claimed in any one of the preceding claims,] The composition of claim 1 wherein the salt is at least 10 times more soluble than the free acid form of the drug at pH 4.5 to 8.0 at 37 °C.

10. (Amended) [A composition as claimed in any Claim 9,] The composition of claim 9 wherein the salt is at least 100 times more soluble than the free acid form of the drug.

11. (Amended) [A composition as claimed in any one of the preceding claims,] The composition of claim 1 wherein the salt is an alkali metal salt.

12. (Amended) [A composition as claimed in Claim 11,] The composition of claim 11 wherein the alkali metal is sodium or potassium.

13. (Amended) [A composition as claimed in any one of the preceding claims] The composition of claim 1 wherein the pellets are administered in a starch capsule coated with a combination of polymethacrylates that is designed to disintegrate and release the pellets in the terminal ileum or in the colon.

14. (Amended) [A composition as claimed in any one of the preceding claims] The composition of claim 1 wherein the drug is used for [the] a treatment selected from the group consisting of ulcerative colitis, Crohn's disease, irritable bowel syndrome, and inflammatory bowel disease.

15. (Amended) A [process] method for [the preparation of] making a composition [according to any one of the preceding claims which comprises] comprising pellets, wherein each pellet comprises an inner core comprising a drug which possesses  
(a) a free acid group which can be converted into an alkali metal salt, and  
(b) a pKa in the range 2.0 to 9.0,  
wherein the inner core is coated with a rate-controlling membrane that determines drug release, wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0 than the corresponding compound containing a free acid group, and wherein the composition is adapted to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition, the method comprising  
making a salt of the drug, and  
coating [said] the salt onto the inner cores.

16. (Amended) [A process as claimed in Claim 15,] The method of claim 15 wherein the salt is prepared as part of a preparation process for the coating of the inner cores.

17. (Amended) A method of improving the controlled release profile of a drug with a rapidly changing solubility in the pH range 4.5 to 8.0, [which comprises administering a composition according to any one of Claims 1 to 14 to a patient, preferably a human patient] the method comprising administering the drug in a composition comprising pellets, wherein each pellet comprises an inner core comprising the drug which possesses

(a) a free acid group which can be converted into an alkali metal salt and

(b) a pKa in the range 2.0 to 9.0,

wherein the inner core is coated with a rate-controlling membrane that determines drug release, wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0 than the corresponding compound containing a free acid group, and wherein the composition is adapted to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition.

18. (Cancelled).

19. (Amended) A method of treatment of ulcerative colitis, Crohn's disease, irritable bowel syndrome, and/or inflammatory bowel disease, [which method comprises] the method comprising

administering to a patient in need of treatment a composition [according to any one of Claims 1 to 14 to a patient, preferably a human patient] comprising pellets, wherein each pellet comprises an inner core comprising a drug which possesses

(a) a free acid group which can be converted into an alkali metal salt, and

(b) a pKa in the range 2.0 to 9.0,

wherein the inner core is coated with a rate-controlling membrane that determines drug release, wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0 than the corresponding compound containing a free acid group, and wherein the composition is adapted to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition.

20. (Cancelled).

21. (New) The composition of claim 1 wherein the pellets are compressed into tablets which are coated to prevent release of drug until the composition reaches the terminal ileum or the colon following oral administration of the composition.

22. (New) The composition of claim 1 wherein the core is between about 0.3 to 5 mm in size.

PCT/97/02726 02 APR 1999

COLONIC DELIVERY OF WEAK ACID DRUGS

This invention relates to novel controlled-release formulations of drugs with pKa values of between 2.0 and 9.0.

5

Drugs that have weak basic functions and/or weak acid functions (i.e. those with pKa values of between 2.0 and 9.0) often have a low and/or variable solubility at pH values normally experienced in the colon (i.e. between 4.5 and 8.0). Consequently, if a drug is delivered to the colon for e.g. local  
10 action, the dissolution of the drug from the tablet, pellet or capsule formulation can be extremely variable, resulting in unsatisfactory controlled release profiles.

Ridogrel ((E)-5-[[[3-pyridinyl[3-(trifluoromethyl)phenyl]methylene]amino]-oxy]pentanoic acid; Janssen Pharmaceutica, Belgium; see US patent 4,963,573) is an example of a drug in which such problems have been found to occur. Ridogrel is a development compound which has been indicated for use in the treatment of *inter alia* inflammatory bowel diseases including Crohn's disease and ulcerative colitis. The drug may be  
20 administered orally in simple pharmaceutical formulations. However, it is anticipated that, if the drug could be delivered to the colonic region of the gastrointestinal tract in a slow release (rate-controlled) fashion, advantages would result. For example, delivery to the colon is likely to concentrate the drug at the required site of action and therefore prevent unwanted  
25 absorption of the drug into the systemic circulation from the small intestine. Further, the controlled release nature of such a formulation is likely to provide good distribution of the drug to the various regions of the large intestine.

General methods for the site specific delivery of drugs to the large bowel have been described in the prior art, including the applicant's pending international patent application WO 95/35100, which discloses the coating of starch capsules with polymers that degrade or dissolve under the conditions found within the different regions of the gastrointestinal tract. In this prior art document, a preferred system was disclosed as comprising a starch capsule coated with a mixture of methacrylate polymers. These polymers only dissolve at pH values above 4.5, thereby allowing a formulation to remain intact in the stomach. Upon entry into the small intestine, the coating on the capsule begins to dissolve. By adjustment of the thickness of the coating of such formulations, it is possible for the capsule to reach the terminal ileum or ascending colon before releasing its contents.

Another granted patent (EP 513 035) describes how a similar effect can be achieved using polymers that are degraded specifically in the colonic environment due to the unique reducing conditions therein. Polymers based upon disulphide bonds have been shown to be effective both *in vitro* and *in vivo*.

20

Alternatively, compositions can be delivered to the colon using other known colon targeting systems. Some examples, which are not exhaustive, are as follows:

The Time Clock Release System™ (Pozzi *et al*, APV Course on Pulsatile Drug Delivery, Königswinter, 20 May 1992) is a tablet system where a tablet core containing the active drug is coated with a layer of pharmaceutical excipients. The excipients hydrate causing the surface layer to burst at a set time. The Pulsincap™ system is an oral pulsatile delivery

system which may be configured to release its drug content at a predetermined time or place within the gastrointestinal tract. The device essentially consists of an impermeable capsule body which contains the drug, sealed at the neck orifice with a hydrogel plug. A normal gelatin cap is then placed onto the body of the device. After ingestion, the gelatin cap dissolves allowing the plug to hydrate. At a predetermined and controlled time, the swollen plug is ejected from the body of the device, thereby releasing the capsule contents and enabling the drug to be released (Wilding et al., Pharm. Res. 9, 654, 1992 and Binns et al., 3rd Eur. Symp. Control. Drug Del., Abstract Book, 1994, p124).

Another system which may be used is the time controlled explosion system, as described in US 4,871,549.

The problem to be solved in the case of the drug ridogrel and similar molecules (for example those which are weakly ionisable in nature, in particular those which are useful in the treatment of inflammation of the intestines and especially thromboxane synthase  $A_2$  inhibitors and thromboxane  $A_2$ /prostaglandin endoperoxide receptor antagonists such as those disclosed in US 4,963,573) is one of (a) achieving a controlled release formulation that will provide good distribution throughout the colon in order to optimise treatment of affected sites, and (b) for such release to be constant (i.e. as near to zero order as possible) and predictable (i.e. reproducible) over an extended period of time.

Controlled release formulations of drugs which target the colon in particular may also be useful for the systemic delivery of therapeutic agents as "once daily" products.

A variety of formulation principles have been disclosed in the prior art for the controlled release of drugs that are weak acids or weak bases. However, it has been found that, in order for a formulation to be distributed evenly at the target site, a multiparticulate pellet formulation is preferred.

- 5 Pellets may be formed by a number of different processes, all well known in the art, including extrusion and spheronisation, as well as the coating of the drug material onto preformed sugar spheres (also known as non-pariels). The drug can be coated onto non-pariels using techniques which are familiar to those skilled in the art. A controlled release layer may then be coated on
- 10 top of the drug layer so as to provide a diffusional barrier. Unfortunately, with drugs such as ridogrel, we have found that a simple diffusional barrier does not provide a satisfactory product. This is because ridogrel has weakly basic functions and a carboxylic acid function and the solubility of the drug in the colonic pH range (4.5 to 8.0) is therefore low, resulting in extremely
- 15 variable dissolution of the drug at such pH values. Thus, a simple formulation, wherein ridogrel is coated onto non-pariel beads, and then overcoated with a rate-controlling membrane, does not result in a formulation possessing a satisfactory release profile.
- 20 However, we have found, surprisingly, that it is possible to achieve a satisfactory formulation comprising drugs such as ridogrel by choosing, instead of the drug itself, an appropriate salt (e.g. alkali metal salt) that has pH independent solubility characteristics. The salt of the drug should be at least 10 times more soluble than the free acid form of the drug and, more
- 25 preferably, greater than 100 times more soluble, as measured in deionized water at the relevant pH range (i.e. 4.5 to 8.0) at 37°C. By "more soluble" we mean that the salt is more soluble over the entire pH range of 4.5 to 8.0. It is then found, surprisingly, that the coated pellet system gives an almost pH independent release profile under *in vitro* conditions as tested in the USP



type 2 dissolution apparatus (The United States Pharmacopoeia, USP23, 1994, page 1791-1793), for example as described hereinafter.

5 The pellet system comprising drug may be coated with a coating material (a rate controlling membrane). The nature and thickness of this coating material may be altered (for example as described hereinafter) to provide a controlled release formulation which will, for example, release the drug over a period of up to 5 hours or over a longer period of up to 12 hours.

10 The present invention thus provides a controlled release formulation comprising an inner core containing, or coated with, a drug and subsequently coated with a rate-controlling membrane that determines drug release, of a drug that contains a weak acid function with a pKa in the range 2.0 to 9.0 (e.g. 3.0 to 9.0) that can be converted into an alkali metal salt wherein the drug is present as a salt that displays higher solubility at pH 4.5  
15 to 8.0 (e.g. 5.0 to 7.0) than the corresponding compound containing a free acid group.

Thus, according to a first aspect of the invention, there is provided a controlled release formulation including an inner core comprising, or coated  
20 with, a drug, which drug possesses (a) a free acid group which can be converted into an alkali metal salt and (b) a pKa in the range 2.0 to 9.0 (e.g. 3.0 to 9.0), which inner core is subsequently coated with a rate-controlling membrane that determines drug release, wherein the drug is present as a salt that displays higher solubility at pH 4.5 to 8.0 (e.g. 5.0 to 7.0) than the  
25 corresponding compound containing a free acid group (referred to hereinafter as "the compositions according to the invention").

Drugs which may be employed in the compositions according to the invention include those which have a rapidly changing solubility in the pH

range 4.5 to 8.0 (i.e. the pH range found in the colon under normal conditions and/or those conditions reported to exist in acute conditions such as ulcerative colitis). Drugs which may be employed include ridogrel, other thromboxane synthase  $A_2$  inhibitors and thromboxane  $A_2$ /prostaglandin endoperoxide receptor antagonists (such as those disclosed in US 4,963,573), and sodium cromoglycate. Particularly preferred drugs include ridogrel.

Suitable salts of the weak acid drugs include ammonium salts and particularly alkali metal salts such as, but not limited to, sodium and potassium salts. Such salts may be prepared in accordance with techniques which are well known to those skilled in the art, including, in the case of alkali metal salts, dissolving the drug in a solution of the relevant hydroxide. For example, an excess of drug may be suspended in the hydroxide solution and stirred for 24 hours. The suspended material may then be removed by filtration and centrifugation and the salt recovered from the filtrate by removal of the water (e.g. using a vacuum oven or by lyophilisation).

The salts may also be prepared as part of a preparation process for the coating of the inner cores. In this case, drug is dissolved in, for example, an appropriate hydroxide solution at a suitable concentration (e.g. 1M) and the pH is adjusted to about 8 by adding acid, such as 0.1M HCl. The salt solution may then be added to a solution of a binder (such as povidone) and the pH adjusted to about 8 (again). This mixture may then be coated onto the inner cores using, for example, a spray coating apparatus. The pellets may, if necessary, be overcoated with a thin layer of plasticised HPMC, which may act as a "primer", in order to obtain a better coating. The inner cores may then be overcoated with the controlled release coating layer (rate-

controlling membrane), which may, for example, consist of Eudragit® RS30D, triethyl citrate and talc, and subsequently dried. The pellets may then be filled into capsules to be coated for delivery to the colon, or compressed into tablets which are then coated.

5

The inner core may comprise drug salt. Drug salt may be incorporated into the inner core during the manufacture of the latter, for example by extrusion/spheronisation.

10 Inner cores which may be employed in the compositions according to the invention include sugar spheres (non-pariels). Suitable sizes of inner cores which may be employed in the compositions according to the invention are in the range 0.3 to 5 mm.

15 In general, the preferred controlled release coating materials which may be employed in the rate-controlling membrane of the compositions according to the invention include those which form a water-insoluble but water-permeable layer and from which release of drug is by diffusion through the layer. By "water-insoluble" we mean "sparingly soluble" as defined in the  
20 British Pharmacopoeia (1988). By "water-permeable" we mean that at least 10% of water, held continuously in contact with the layer, will penetrate the layer within two hours (the degree of permeation may be measured in accordance with techniques which are well known to those skilled in the art). The coating polymer may be inherently water-permeable or become  
25 water-permeable through the incorporation of other additives such as plasticisers or pore forming agents. Suitable coating polymers include methacrylate copolymers, ethylcellulose, etc. Preferred coating materials are the permeable, water insoluble grades of pharmaceutical polymethacrylates (Eudragit® RL100, Eudragit RS100/RS30D, Eudragit

NE30D, Rohm Pharma, Darmstadt, Germany) and ethylcellulose. Eudragit RL100 and RS100 contain quaternary ammonium groups which may interact with ionised weakly acidic drugs and hence the most preferred coating materials are ethylcellulose and Eudragit NE30D. Ethylcellulose may be applied as a solution in an organic solvent or as a proprietary water-based latex preparation (e.g. Aquacoat®, FMC, Philadelphia, USA or Surelease®, Colorcon, West Point, USA).

The thickness of the rate-controlling membrane required for use in the compositions according to the invention will depend on the permeability of the polymer to the drug in question and the duration of release required from the coated formulation. However, the amount employed will typically be in the range 2% w/w to 25% w/w of the formulation, or will be an amount to produce a thickness in the range 80 µm to 300 µm.

The compositions according to the invention may be adapted to deliver therapeutic agent to the colonic region of the gastrointestinal tract, especially the proximal colon. Preferably, a means is provided to prevent release of drug until the formulation reaches the colonic region.

By "colonic region of the gastrointestinal tract" we mean the terminal ileum and the colon.

The compositions according to the invention, may thus be filled into the various known delivery systems intended for targeting the colonic region, including those described above, and including the coated capsules described above. Alternatively, the compositions according to the invention may be further coated with an enteric layer that slowly dissolves within the small intestine to allow exposure of the rate-controlling membrane to the

liquid in the terminal ileum and/or the colon for subsequent release. In a similar fashion to the coated starch capsules disclosed in international patent application WO 95/35100, the coating may be an enteric polymer that dissolves in the small intestine or a polymeric or polysaccharide material that is not degraded until it meets the specific conditions found in the colon. Such degradation may be through direct chemical effect, e.g. the degradation of disulphide bonds under reducing conditions, or the degradation of polysaccharide materials under the effects of the microflora found within the colon.

Preferred coating materials for targeting to the colon, which may be used in capsules, tablets or pellets including the compositions according to the invention, are those which dissolve at pH of 4.5 or above. In this way, the coatings only begin to dissolve once they have left the stomach and have entered the small intestine. A thick layer of coating is thus preferably provided which will dissolve in about 2 to 5 hours, thereby allowing the capsule underneath to break-up only when it has reached the terminal ileum and/or the colon. Such a coating can be made from a variety of polymers such as cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP) and shellac, as described by Healy in his article "Enteric Coatings and Delayed Release", Chapter 7 in *Drug Delivery to the Gastrointestinal Tract*, eds. Hardy *et al*, Ellis Horwood, Chichester, 1989. For coatings of the polymers, a thickness of 150 to 300  $\mu\text{m}$  is suitable.

Especially preferred materials are methylmethacrylates or copolymers of methacrylic acid and methylmethacrylate. Such materials are available as Eudragit® enteric polymers (Rohm Pharma, Darmstadt, Germany; see above). These are copolymers of methacrylic acid and methylmethacrylate.

Preferred compositions are based on Eudragit L100 and Eudragit S100. Eudragit L100 dissolves at pH 6 and upwards and comprises 48.3% methacrylic acid units per g of dry substance; Eudragit S100 dissolves at pH 7 and upwards and comprises 29.2% methacrylic acid units per g of dry substance. Preferred coating compositions are based on Eudragit L100 and Eudragit S100 in the range 100 parts L100:0 parts S100 to 20 parts L100:80 parts S100. The most preferable range is 70 parts L100:30 parts S100 to 80 parts L100:20 parts S100. As the pH at which the coating begins to dissolve increases, the thickness necessary to achieve colon specific delivery decreases. For formulations where the ratio of Eudragit L100:S100 is high, a coat thickness of the order 150-200  $\mu\text{m}$  is preferable. This is equivalent to 70-110 mg of coating for a size 0 capsule. For coatings where the ratio Eudragit L100:S100 is low, a coat thickness of the order 80 to 120  $\mu\text{m}$  is preferable, which is equivalent to 30 to 60 mg coating for a size 0 capsule.

15

The colonic region has a large population of microbial anaerobic organisms providing reducing conditions. Thus, the coating may suitably comprise a material which is redox-sensitive. Such coatings may comprise azopolymers which may, for example, consist of a random copolymer of styrene and hydroxyethyl methacrylate, cross-linked with divinylazobenzene synthesised by free radical polymerisation (the azopolymer being broken down enzymatically and specifically in the colon), or disulphide polymers (see PCT/BE91/00006 and Van den Mooter, *Int. J. Pharm.* 87, 37 (1992)).

20

Other materials which may be used to provide release in the colon include amylose. For example, a coating composition can be prepared by mixing amylose-butan-1-ol complex (glassy amylose) with Ethocel® aqueous dispersion (Milojevic *et al.*, *J. Control. Rel.*, 38, 75 (1996)), or a coating formulation comprising an inner coating of glassy amylose and an outer

25

coating of cellulose or acrylic polymer material (Allwood *et al.*, GB9025373.3), calcium pectinate (Rubenstein *et al.*, Pharm. Res., **10**, 258, (1993)), pectin, a polysaccharide which is totally degraded by colonic bacterial enzymes (Ashford *et al.*, Br. Pharm. Conference, 1992 Abstract 5 13), chondroitin sulphate (Rubenstein *et al.*, Pharm. Res. **9**, 276, 1992) and resistant starches (Allwood *et al.*, PCT WO89/11269, 1989), dextran hydrogels (Hovgaard and Brøndsted, 3rd Eur. Symp. Control. Drug Del., Abstract Book, 1994, 87), modified guar gum, such as borax modified guar gum (Rubenstein and Gliko-Kabir, S.T.P. Pharma Sciences **5**, 41 (1995)), 10 *p*-cyclodextrin (Sie ke *et al.*, Eur. J. Pharm. Biopharm. **40** (suppl.), 335 (1994)), saccharide containing polymers, by which we include a polymeric construct comprising a synthetic oligosaccharide-containing biopolymer, including methacrylic polymers covalently coupled to oligosaccharides such as cellobiose, lactulose, raffinose, and stachyose, or saccharide-containing 15 natural polymers including modified mucopolysaccharides such as cross-linked chondroitin sulfate and metal pectin salts, for example calcium pectate (Sintov and Rubenstein; PCT/US91/03014); methacrylate-galactomannan (Lehmann and Dreher, Proc. Int. Symp. Control. Rel. Bioact. Mater. **18**, 331 (1991)), pH-sensitive hydrogels (Kopecek *et al.*, J. 20 Control. Rel. **19**, 121 (1992)) and resistant starches, e.g. glassy amylose, that are not broken down by the enzymes in the upper gastrointestinal tract but are degraded by enzymes in the colon.

It will be well understood by those skilled in the art that further excipients 25 may be employed in the compositions according to the invention. For example, further excipients which may be employed include diluents such as microcrystalline cellulose (e.g. Avicel®, FMC), lactose, dicalcium phosphate and starch(es); disintegrants such as microcrystalline cellulose, starch(es) and cross-linked carboxymethylcellulose; lubricants such as

magnesium stearate and stearic acid; granulating agents such as povidone; and release modifiers such as hydroxypropyl methylcellulose and hydroxypropyl cellulose. Suitable quantities of such excipients will depend upon the identity of the active ingredient(s) and particular dosing form which is used.

Appropriate quantities of drug salts which may be employed in the compositions according to the invention will depend upon the agent which is used. However, it will be clear to the skilled person that doses of drug salts can be readily determined non-inventively. Suitable doses for selected drugs in the present invention (e.g. ridogrel) are in the range 1 to 200 mg, preferably 2 to 100 mg and more preferable, 5 to 50 mg.

Compositions according to the invention have been found to have the advantage that they provide an improved release profile in respect of drugs which have a rapidly changing solubility, and therefore an extremely variable dissolution, in the colonic pH range (4.5 to 8.0).

Thus, according to a further aspect of the invention there is provided a method of improving the release profile of a drug with a rapidly changing solubility in the pH range 4.5 to 8.0 which method comprises administering a composition according to the invention to a patient, preferably a human patient.

In view of the advantageous properties of the compositions according to the invention, they are useful in the treatment of conditions such as ulcerative colitis, Crohn's disease, irritable bowel syndrome and/or inflammatory bowel disease, when adapted for delivery to the colonic region.



According to a further aspect of the invention there is provided a method of treatment of ulcerative colitis, Crohn's disease, irritable bowel syndrome and/or inflammatory bowel disease which method comprises administering a composition according to the invention to the colonic region of a patient,  
5 preferably a human patient.

### Brief Description of the Figures

Figure 1 shows the release of ridogrel at pH 6 and pH 7 from 0.61 to 0.7  
10 mm pellets coated with 3.7% Eudagrit RS (USP method 2; 37°C).

Figure 2 shows the dissolution of (a) ridogrel and (b) sodium ridogrel at pH 5, 6 and 7.

15 Figure 3 shows the release of ridogrel (as the sodium salt) at pH 5, 6 and 7 from 0.6 to 0.71 mm pellets coated with 19% w/w Eudagrit RS (USP method 2; 37°C).

Figure 4 shows the release of ridogrel (as the sodium salt) from 1 to 1.18  
20 mm pellets with three levels of Aquacoat coating (USP method 2; 37°C).

Figure 5 shows the release of ridogrel (as the sodium salt) at pH 5, 6 and 7 from 1 to 1.18 mm pellets containing 14% Aquacoat coating (USP method 2; 37°C).

25

Figure 6 shows the dissolution performance of starch capsules containing inner cores comprising sodium ridogrel.

Figure 7 shows the plasma profiles of three colon targeted formulations as determined in a human clinical trial, pharmacoscintigraphy study.

The invention is illustrated, but in no way limited, by the following  
5 examples.

#### **Example 1 (Comparative example)**

##### **Preparing ridogrel pellets coated with polymethacrylate (Eudragit RS)**

A solution of 20 g of ridogrel (Janssen Pharmaceutica; Belgium) and 2 g of  
10 povidone (Kollidon 30) in 250 mL of ethanol was prepared. This solution  
was spray-coated onto 400 g of sugar spheres (600-710  $\mu$ m, NP Pharma,  
France) using an Aeromatic STREA-1 coater. The pellets were assayed for  
ridogrel content by a spectrophotometric method. To prepare the coating  
solution of sustained release polymer, 35 g of talc was first dispersed in 250  
15 mL of water and 9 g of triethyl citrate was added. 150 mL of Eudragit  
RS30D (Rohm Pharma) was then added to the talc dispersion. 280 g of the  
ridogrel-coated pellets were then coated with the Eudragit solution in the  
STREA-1 using an inlet temperature of 50°C. 100 mL of solution was  
applied to the pellets. The pellets were then dried overnight at 40°C and  
20 assayed for ridogrel content using a spectrophotometric method (UV).

The dissolution performance of the pellets was measured using the BP/USP  
method 2 (USP23, 1994, page 1791-1793; paddles, 50 rpm) with 900 mL of  
either pH 6 or pH 7 phosphate buffer as the test medium. In Figure 1, the  
25 dissolution performance of the pellets is shown. Compared to the  
performance of the pellets at pH 7, there was a substantial reduction in the  
rate of drug release at pH 6. For example, after 4 hours, approximately  
24% of the ridogrel had been released at pH 6, compared to 74% at pH 7.

## Example 2

### Solubility of ridogrel and sodium ridogrel

In accordance with the invention, sodium ridogrel was prepared as follows:

- i) 0.1 g of sodium hydroxide was dissolved in 20 mL of water;
- 5 ii) 1.5 g of ridogrel was added to the sodium hydroxide solution to form a suspension;
- iii) the ridogrel suspension was placed into a sonic bath for 10 minutes;
- iv) the suspension was passed through a 0.45  $\mu$ m membrane filter,
- 10 the filtrate was collected, diluted by adding 20 mL of water, and lyophilised overnight; and
- v) the lyophilised sodium ridogrel was gently milled in a mortar to produce a fine powder.

- 15 Into each of three size 2 hard gelatin capsules was weighed 10 mg of ridogrel. Into another three capsules was weighed 10 mg of the sodium ridogrel lyophilisate. The dissolution of ridogrel and sodium ridogrel into 900 mL of phosphate buffer at pH 5, 6 and 7 was tested (USP apparatus 2, 100 rpm). The dissolution rate of ridogrel (as the parent acid) increased as
- 20 the pH was raised (Figure 2a). In contrast, the rate of dissolution of sodium ridogrel was largely independent of pH (Figure 2b).

Therefore there was a significant reduction in the rate of dissolution of ridogrel as the pH was reduced from 7 to 5, the pH range likely to be

25 encountered in the large intestine. However, in this pH range, the sodium salt of ridogrel had a greatly improved dissolution rate.

### Example 3

#### Preparation of pellets coated with sodium ridogrel and Eudragit

Pellets were prepared containing the sodium salt of ridogrel. 20 g of ridogrel was dissolved in approximately 60 mL of 1M sodium hydroxide solution. The solution of sodium ridogrel was adjusted down to pH 8 by adding 0.1M hydrochloric acid and made up to 100 mL with water. 40 g of povidone (Kollidon 30; BASF) was dissolved in 200 mL of water. The povidone solution was added to the ridogrel solution and a precipitate was formed, which was dissolved by adding sodium hydroxide to adjust the solution to pH 8. The povidone/sodium ridogrel solution was applied to 1 kg of sugar spheres (0.6-0.71 mm) using the Aeromatic STREA-1 coater. After coating, the pellets were relatively tacky which could have been due to the hygroscopic nature of the povidone and/or the sodium ridogrel. To remove this tackiness, the pellets were overcoated with a thin layer of HPMC: The HPMC solution was prepared by dissolving 30 g of Methocel® E5 in 600 mL of water and adding 3 g of PEG400 as a plasticiser. The pellets were assayed for ridogrel content.

450 mL of Eudragit coating solution was prepared as follows: 150 mL of Eudragit RS30D, 9 g of triethyl citrate, 35 g of talc, 250 mL of water. The solution was applied to 400 g of sodium ridogrel/povidone/HPMC pellets. The coated pellets were dried overnight at 40°C. The pellets were assayed for ridogrel content.

The dissolution performance of the pellets at pH 5, 6 and 7 is shown in Figure 3. There was a small reduction in the rate of drug release as the pH was decreased. This demonstrated that the rate of release of ridogrel as the sodium salt was largely independent of pH, which was in marked contrast to pellets containing ridogrel as the parent acid (see Figure 1).

#### Example 4

##### Preparation of pellets coated with sodium ridogrel and ethylcellulose

Pellets were prepared with an ethylcellulose outer layer. A water-based ethylcellulose preparation, Aquacoat® (FMC, Philadelphia), was used in order to eliminate the use of organic solvents in the coating process. Pellets were prepared as follows:

20 g of ridogrel was weighed into a beaker and dissolved in 56 mL of 1M sodium hydroxide solution. 40 g of povidone (Kollidon K30) was weighed into a large beaker and dissolved in 500 mL of water. The ridogrel solution was added to the povidone solution. The pH change resulted in precipitation of ridogrel. Sodium hydroxide solution was added to dissolve the ridogrel. The pH of the solution was adjusted to pH 8 using 0.1M hydrochloric acid and made up to 600 mL with water. 1 kg of sugar spheres (1.00-1.18 mm diameter) were coated with the sodium ridogrel/povidone solution using the Aeromatic STREA-1 coater (inlet temperature was 55°C).

An overcoat of HPMC was applied to the sodium ridogrel/povidone layer.

The HPMC solution was prepared by dispersing 20 g of HPMC (Methocel® E5) in 200 mL of hot water. The dispersion was cooled in ice (whilst being stirred) and 2 g of PEG400 was added as a plasticiser. The solution was made up to 400 mL with water. The HPMC solution was applied using the STREA-1 at an inlet temperature of 55°C. The completed pellets were left to dry overnight at room temperature. The Aquacoat mixture was prepared by stirring together 300 mL of Aquacoat and 21.6 g of dibutyl sebacate for 1 hour, followed by the addition of 300 mL of water. 500 g of sodium ridogrel/povidone/HPMC pellets were transferred to the Aeromatic and coated with the Aquacoat mixture (coating temperature

40°C). Pellet samples (20 g) were collected at intermediate points in the coating run, after the application of approximately 300 mL and 450 mL of the coating solution. After coating, the pellet samples were spread into trays and dried overnight at 60°C.

5 The dissolution performance of the pellets at pH 7 is shown in Figure 4. The dissolution performance of the pellets containing 14% coating at pH 5, 6 and 7 is shown in Figure 5. Drug release was independent of pH. The release of drug from these samples was complete. This was in contrast to  
10 the Eudragit-coated pellets where drug release was incomplete. This was probably due to an interaction between negatively-charged ridogrel ions and positively charged quaternary ammonium groups within Eudragit RS. Hence ethylcellulose is a preferred polymer for use in preparing ridogrel controlled release pellets.

### 15 Example 5

#### Preparation of Formulations for Testing in Human Clinical Trial, Phase 1.

Pellets were prepared with an ethylcellulose outer layer as the rate  
20 controlling membrane. A water based ethylcellulose preparation, Aquacoat® (FMC, Philadelphia) was used. 10 g of ridogrel was weighed into a beaker and dissolved in 28 mL of 1 M sodium hydroxide solution and made up to 100 mL with water. 20 g of povidone (Kollidon K 30) was weighed into a large beaker and dissolved in 200 mL of water. The  
25 ridogrel solution was added to the povidone solution. 1M sodium hydroxide solution was added to dissolve the precipitated ridogrel and the pH was adjusted to 8 with 0.1 M hydrochloric acid.

500 g of sugar pellets (1-1.18 mm in diameter) were coated with the sodium ridogrel/povidone solution using the aromatic STREA-1 coater (inlet temperature 55°C). An overcoat of HPMC was applied to the sodium ridogrel/povidone layer. The HPMC solution was prepared by  
5 dispersing 20 g of HPMC (Methocel E5) in 200 mL hot water. The dispersion was cooled in ice (whilst being stirred) and 1 g of PEG 400 was added as a plasticiser and the volume made up to 400 mL with water. The HPMC solution was applied using the STREA - 1 at an inlet temperature of 55°C. The completed pellets were left to dry overnight at room  
10 temperature. 30 g of pellets were removed ("immediate release pellets"; A).

The Aquacoat mixture was prepared by stirring together 300 mL of Aquacoat and 21.6 g of dibutyl sebacate for 1 hour, followed by the  
15 addition of 300 mL of water. About 500 g of sodium ridogrel/povidone/HPMC pellets were transferred to the Aeromatic STREA-1 coater and coated with Aquacoat mixture (coating temperature 45°C). Pellet samples of 35 g were collected after the application of 450 mL ("8 hour release pellets"; B) and after the application of 600 mL ("12  
20 hour release pellets"; C) of Aquacoat. After coating the pellet samples were spread into trays and dried overnight at 60°C.

The three different pellet samples were filled into starch capsules (Capill) with approximately 425 mg in each capsule. The capsules were coated  
25 with a Eudragit solution consisting of Eudragit S100/Eudragit L100 1:3, dibutyl sebacate, talc, isopropanol and water in the Aeromatic STREA - 1 coater. The coating conditions used were drying temperature 25°C, fan speed 6, atomisation pressure 1 bar and application rate 1.5 - 4.0 mL/minute. The weight gain per capsule was 78 mg.

The dissolution performance of the capsules at 37°C for 2 hours in 0.1 M HCl, followed by phosphate buffer, pH 6.8 in a Vankel 6010 dissolution apparatus (baskets rotated at 50 rpm) is shown in Figure 6. (Values are the mean of the two determinations.) The difference in rate of dissolution between the 3 different pellet samples is clearly seen.

### **Example 6**

#### **Phase 1 human clinical trial, pharmacoscintigraphy study**

The clinical trial was a four way crossover study in 8 healthy male volunteers, aged 18-35 years. Three of the doses administered were the colon targeted capsule formulations described in Example 5. These formulations were radiolabelled with a gamma emitting isotope (indium - 111). The fourth formulation was a conventional immediate release tablet, and was not radiolabelled. On each study day, blood samples were collected for ridogrel analysis. Plasma samples were analysed by Janssen Pharmaceutica. Of the capsules dosed, 21 disintegrated at the ileocaecal junction or in the colon and two in the lower small intestine. The plasma ridogrel analysis showed that for all three colon targeted formulations, peak plasma concentrations occurred much later than with the conventional tablet (7.5 h, 12.5 - 13 h as compared with 0.9 h). The maximum plasma ridogrel concentrations were much lower for the colon targeted formulations than of the conventional tablet, and plasma concentrations were sustained for a longer period. Furthermore the maximum plasma concentration for the immediate release, colon targeted formulation was higher than for the sustained release formulations. The plasma profiles for the colon targeted formulations are shown in Figure 7. (Values are the mean for all volunteers, omitting those where the dose was



retained in the stomach. For Formulation A, n = 6; Formulation B, n = 7; Formulation C, n = 8.)

1. A controlled release composition including pellets, each comprising an inner core, which core comprises, or is coated with, a drug, which drug  
5 possesses (a) a free acid group which can be converted into an alkali metal salt and (b) a pKa in the range 2.0 to 9.0, which inner core is subsequently coated with a rate-controlling membrane that determines drug release, wherein the drug is present as a salt that displays higher solubility at pH 4.5. to 8.0 than the corresponding compound containing a free acid group,  
10 and wherein the composition is adapted to prevent release of drug until the composition reaches the terminal ileum or the colon.
2. A composition as claimed in Claim 1 wherein the drug is a thromboxane synthase A<sub>2</sub> inhibitor or a thromboxane A<sub>2</sub>/prostaglandin endoperoxide  
15 receptor antagonist.
3. A composition as claimed in Claim 2 wherein the drug is ridogrel.
4. A composition as claimed in any one of Claims 1 to 3, wherein the rate-  
20 controlling membrane comprises a material which forms a water-insoluble but water-permeable layer and from which release of drug is by diffusion through the layer.
5. A composition as claimed in Claim 4, wherein the rate-controlling  
25 membrane is formulated from a methacrylate copolymer or ethylcellulose.
6. A composition as claimed in Claim 5, wherein the rate-controlling membrane is formulated from ethylcellulose or Eudragit NE30D.

7. A composition as claimed in Claim 6 where the rate-controlling membrane is ethylcellulose.
8. A composition as claimed in any one of the preceding claims, wherein  
5 the inner core is a sugar sphere.
9. A composition as claimed in any one of the preceding claims, wherein the salt is at least 10 times more soluble than the free acid form of the drug at pH 4.5 to 8.0 at 37°C.
- 10
10. A composition as claimed in any Claim 9, wherein the salt is at least 100 times more soluble than the free acid form of the drug.
11. A composition as claimed in any one of the preceding claims, wherein  
15 the salt is an alkali metal salt.
12. A composition as claimed in Claim 11, wherein the alkali metal is sodium or potassium.
- 20
13. A composition as claimed in any one of the preceding claims wherein the pellets are administered in a starch capsule coated with a combination of polymethacrylates that is designed to disintegrate and release the pellets in the terminal ileum or in the colon.
- 25
14. A composition as claimed in any one of the preceding claims wherein the drug is used for the treatment of ulcerative colitis, Crohn's disease, irritable bowel syndrome, inflammatory bowel disease.

15. A process for the preparation of a composition according to any one of the preceding claims which comprises making a salt of the drug and coating said salt onto the inner cores.

5 16. A process as claimed in Claim 15, wherein the salt is prepared as part of a preparation process for the coating of the inner cores.

17. A method of improving the release profile of a drug with a rapidly changing solubility in the pH range 4.5 to 8.0, which comprises  
10 administering a composition according any one of Claims 1 to 14 to a patient, preferably a human patient.

18. The use of a composition according any one of Claims 1 to 14 in the manufacture of a medicament for use in the improved release profile of a  
15 drug with a rapidly changing solubility in the pH range 4.5 to 8.0.

19. A method of treatment of ulcerative colitis, Crohn's disease, irritable bowel syndrome and/or inflammatory bowel disease which method comprises administering a composition according to any one of Claims 1 to  
20 14 to a patient, preferably a human patient.

20. The use of a composition according any one of Claims 1 to 14 in the manufacture of a medicament for the treatment of ulcerative colitis, Crohn's disease, irritable bowel syndrome and/or inflammatory bowel  
25 disease.

AMENDED CLAIMS  
PAGE 2

Figure 1






Figure 2



3/7


Figure 3



4/7

09/269903  
PCT/GB97/01726


Figure 4






5/7

Figure 5




6/7

Figure 6



7/7

Figure 7



Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00, CMB 0651-0032  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing **OR** ☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

<b>Attorney Docket Number</b>	WC 131
<b>First Named Inventor</b>	Peter James Watts
<b>COMPLETE IF KNOWN</b>	
<b>Application Number</b>	09 / 269,903
<b>Filing Date</b>	April 2, 1999
<b>Group Art Unit</b>	
<b>Examiner Name</b>	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**COLONIC DELIVERY OF WEAK ACID DRUGS**

the specification of which (Title of the Invention)

☐ is attached hereto  
OR

☒ was filed on (MM/DD/YYYY) 10/06/1997 as United States Application Number or PCT International

Application Number **PCT/GB97/02726** and was amended on (MM/DD/YYYY) (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?
9620709.7	Great Britain	10/04/1996	<input type="checkbox"/>	<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
PCT/GB97/02726	PCT	10/06/1997	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
		<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

**Burden Hour Statement:** This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 131

Please type a plus sign (+) inside this box → ☒

PTO/SB/01 (12-97)  
Approved for use through 9/30/00, OMB 0651-0032  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number  OR ☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Patrea L. Pabst	31,284		
Robert A. Hodges	41,074		
Kevin W. King	42,737		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label  OR ☒ Correspondence address below

Name	Patrea L. Pabst		
Address	Arnall Golden & Gregory, LLP		
Address	2800 One Atlantic Center, 1201 West Peachtree Street		
City	Atlanta	State	GA
ZIP	30309-3450		
Country	United States	Telephone	(404)873-8794
Fax	(404)873-8795		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Peter James		Watts	
Inventor's Signature	<i>P. J. Watts</i>	Date	10/14/99
Residence: City	Nottingham	State	GB
Post Office Address	Flat 2, 47 Highfield Road		
Post Office Address	West Bridgford		
City	Nottingham	State	GB
ZIP	NG2 6DR		
Country	GB		

☐ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto